Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein turnover in women

被引:10
|
作者
Toth, Michael J.
Sites, Cynthia K.
Matthews, Dwight E.
Casson, Peter R.
机构
[1] Univ Vermont, Hlth Sci Res Facil 126B, Dept Med, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
关键词
estrogen; menopause; fat-free mass; sarcopenia; progesterone;
D O I
10.1152/ajpendo.00600.2005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The age-related decline in fat-free mass is accelerated in women after menopause. The role of ovarian hormone deficiency in the regulation of fat-free mass, however, has not been clearly defined. To address this question, we examined the effect of ovarian hormone suppression on whole body protein metabolism. Whole body protein breakdown, oxidation, and synthesis were measured using [C-13] leucine in young, healthy women with regular menstrual patterns before and after 2 mo of treatment with gonadotropin-releasing hormone agonist (GnRHa; n = 6) or placebo (n = 7). Protein metabolism was measured under postabsorptive and euglycemic-hyperinsulinemic-hyperaminoacidemic conditions. Ovarian suppression did not alter whole body or regional fat-free mass or adiposity. In the postabsorptive state, GnRHa administration was associated with reductions in protein breakdown and synthesis (P < 0.05), whereas no change in protein oxidation was noted. Under euglycemic-hyperinsulinemic-hyperaminoacidemic conditions, a similar reduction (P < 0.05) in protein synthesis and breakdown was noted, whereas, protein oxidation increased (P < 0.05) in the placebo group. Testosterone, steroid hormone precursors, insulin-like growth factor I, and their respective binding proteins were not altered by GnRHa administration, and changes in these hormones over time were not associated with GnRHa-induced alterations in protein metabolism, suggesting that changes in protein turnover are not due to an effect of ovarian suppression on other endocrine systems. Our findings provide evidence that endogenous ovarian hormones participate in the regulation of protein turnover in women.
引用
收藏
页码:E483 / E490
页数:8
相关论文
共 50 条
  • [21] Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger
    Fatemi, Human Mousavi
    Garcia-Velasco, Juan
    FERTILITY AND STERILITY, 2015, 103 (04) : 870 - 873
  • [22] BINDING OF GONADOTROPIN-RELEASING HORMONE AGONIST TO RAT OVARIAN GRANULOSA-CELLS
    JONES, PBC
    CONN, PM
    MARIAN, J
    HSUEH, AJW
    LIFE SCIENCES, 1980, 27 (22) : 2125 - 2132
  • [23] OVARIAN RESPONSE TO HUMAN MENOPAUSAL GONADOTROPIN AFTER THERAPY WITH THE GONADOTROPIN-RELEASING HORMONE AGONIST LEUPROLIDE
    NADER, S
    BERKOWITZ, AS
    WINKEL, CA
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (02) : 403 - 404
  • [24] Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
    Del Mastro, Lucia
    Lambertini, Matteo
    ONCOLOGIST, 2015, 20 (11): : 1233 - 1235
  • [25] RECOVERY OF HORMONE-SECRETION AFTER CHRONIC GONADOTROPIN-RELEASING HORMONE AGONIST ADMINISTRATION IN WOMEN WITH POLYCYSTIC OVARIAN DISEASE
    DEZIEGLER, D
    STEINGOLD, K
    CEDARS, M
    LU, JKH
    MELDRUM, DR
    JUDD, HL
    CHANG, RJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (06): : 1111 - 1117
  • [26] STEROID-SECRETION IN POLYCYSTIC OVARIAN DISEASE AFTER OVARIAN SUPPRESSION BY A LONG-ACTING GONADOTROPIN-RELEASING HORMONE AGONIST
    CHANG, RJ
    LAUFER, LR
    MELDRUM, DR
    DEFAZIO, J
    LU, JKH
    VALE, WW
    RIVIER, JE
    JUDD, HL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (05): : 897 - 903
  • [27] Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist
    Schröder, AK
    Schöpper, B
    Al-Hasani, S
    Löning, M
    Diedrich, K
    Ludwig, M
    FERTILITY AND STERILITY, 2003, 79 (03) : 648 - 650
  • [28] Suppression and flare regimens of gonadotropin-releasing hormone agonist - Use in women with different basal gonadotropin values in an in vitro fertilization program
    Toth, TL
    Awwad, JT
    Veeck, LL
    Jones, HW
    Muasher, SJ
    JOURNAL OF REPRODUCTIVE MEDICINE, 1996, 41 (05) : 321 - 326
  • [29] Gonadotropin-releasing hormone agonist induces downregulation of tensin 1 in women with endometriosis
    Rahmawati, Endah
    Yang, Wei-Chung V.
    Lei, Yen-Ping
    Maurya, Pawan K.
    Chen, Huei-Wen
    Tzeng, Chii-Ruey
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2019, 98 (02) : 222 - 231
  • [30] Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
    Arani, Kobra Shiasi
    Heidari, Fatemeh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 13 (03)